Max Kholin

Impact

Max Kholin is a co-founder of Gero, the Singapore-based biotechnology company that applies physics and machine learning to large-scale human data to understand the dynamics of aging and to find interventions that target it. As Chief Corporate Development Officer he leads the company's business development, financing and partnerships, complementing the scientific direction of co-founder and chief executive Peter Fedichev. Gero is known for work using UK Biobank and other longitudinal data to model the loss of physiological resilience with age and to argue for the existence of a limit on human lifespan, and for a drug-discovery collaboration with Pfizer on fibrotic disease. Kholin has helped raise the company's disclosed equity financing, reported at about US$34 million as of 2026, and represents Gero in the longevity investment and partnership community.

Metrics

• USD 34M raised by Gero as of 2026-06 source ↗

Links

Research fields

Associated labs